Short answer
Strata Critical Medical, Inc. (SRTA) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $5M (down 93.0% year over year) with net income of $57M.
Q3 2025 key financials · XBRL
- Revenue
- $5M
- −93.0% YoY · −92.6% QoQ
- Net income
- $57M
- +3038.4% YoY · +1634.0% QoQ
- Operating margin
- -65.0%
- EPS (diluted)
- $0.71
- +2466.7% YoY · +1520.0% QoQ
Source: XBRL data from the Strata Critical Medical, Inc. (SRTA) Q3 2025 10-Q on SEC EDGAR. USD.
Strata Critical Medical, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $49.3M, up $13.2M from $36.1M YoY
- Operating loss $5.6M vs $7.1M YoY
- Cost of revenue $37.7M vs $28.6M YoY
- Passenger sale generated $70.2M net proceeds
- Donor-organ availability decreased in recent months, creating a potential headwind
Risk Factors
- Passenger-segment risks no longer material after August 29, 2025 sale to Joby Buyer
- Keystone integration risk following September 16, 2025 acquisition, including retention of key employees and clients
- Contingent consideration risk: up to $35.0 million potentially payable in cash or Joby Aviation shares
- Clinical-services liability risk from negative outcomes, investigations, litigation, and uninsured judgments
- Financial reporting comparability risk from Passenger results classified as discontinued operations across periods
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Strata Critical Medical, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.